Form 4: Belite Bio CSO Nathan Mata Executes Stock Sale

Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of Belite Bio, Inc. via a pre-arranged 10b5-1 trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., sold a total of 1,000 American depositary shares (ADS) on April 15, 2026.
• The transactions were executed in five separate tranches at weighted average prices ranging from $167.5792 to $171.19 per share.
• Following these transactions, the reporting person retains beneficial ownership of 15,666 ADS.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-planned, automated mechanism rather than a discretionary market move.

Positives

• The sale was executed under a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The sale represents a reduction in the equity stake held by a key member of the executive leadership team.

Risks

• Future sales by insiders could potentially signal a lack of confidence in the company's long-term valuation or clinical progress.

Future Outlook

No specific forward-looking guidance regarding company operations or financial performance was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives to diversify personal holdings and should not necessarily be interpreted as a negative reflection on the company's clinical or commercial prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for biotech executives to manage equity compensation while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the executive's holdings.

Next Steps

• Continued monitoring of future Form 4 filings for additional insider activity.

Key Dates

Keywords

Belite Bio, BLTE, Insider Trading, Form 4, Biotech, Nathan Mata